Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study.

Mean (SD) CD4 T-cell counts in the ETR group increased from 702 (333) to 749 (345) cells/μL, although the difference did not reach statistical significance (p = 0.25), and did not vary in the control group [from 717 (232) to 713 (270) cells/μL; p = 0.81].

also in 111,027 other papers